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device success compared with a self-expandable transcatheter heart valve.
OBJECTIVES The aim of this study was to evaluate clinical and echocardiographic outcome data at longer term
follow-up.
METHODS The investigator-initiated trial randomized 241 high-risk patients with symptomatic severe aortic stenosis
and anatomy suitable for treatment with both balloon- and self-expandable transcatheter heart valves to transfemoral
transcatheter aortic valve replacement with either device. Patients were followed-up for 1 year, with assessment of
clinical outcomes and echocardiographic evaluation of valve function.
RESULTS At 1 year, the rates of death of any cause (17.4% vs. 12.8%; relative risk [RR]: 1.35; 95% conﬁdence interval
[CI]: 0.73 to 2.50; p ¼ 0.37) and of cardiovascular causes (12.4% vs. 9.4%; RR: 1.32; 95% CI: 0.63 to 2.75; p ¼ 0.54) were
not statistically signiﬁcantly different in the balloon- and self-expandable groups, respectively. The frequencies of all
strokes (9.1% vs. 3.4%; RR: 2.66; 95% CI: 0.87 to 8.12; p ¼ 0.11) and repeat hospitalization for heart failure (7.4% vs.
12.8%; RR: 0.58; 95% CI: 0.26 to 1.27; p ¼ 0.19) did not statistically signiﬁcantly differ between the 2 groups. Elevated
transvalvular gradients during follow-up were observed in 4 patients in the balloon-expandable group (3.4% vs. 0%;
p ¼ 0.12); all were resolved with anticoagulant therapy, suggesting a thrombotic etiology. More than mild paravalvular
regurgitation was more frequent in the self-expandable group (1.1% vs. 12.1%; p ¼ 0.005).
CONCLUSIONS Despite the higher device success rate with the balloon-expandable valve, 1-year follow-up of patients
in CHOICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis:
Medtronic CoreValve Versus Edwards SAPIEN XT Trial), with limited statistical power, revealed clinical outcomes after
transfemoral transcatheter aortic valve replacement with both balloon- and self-expandable prostheses that were not
statistically signiﬁcantly different. (A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic
Stenosis: The CHOICE Trial; NCT01645202) (J Am Coll Cardiol 2015;66:791–800) © 2015 by the American College of
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792I n the past decade, transcatheter aorticvalve replacement (TAVR) has evolvedfrom a novel technology to an estab-
lished therapy for high-risk patients with se-
vere symptomatic aortic valve stenosis (1–3).
Currently, several transcatheter heart valves
(THVs) have been approved or are being
evaluated in clinical trials, but broadly, there
are 2 main THVs in clinical use: balloon-
expandable and self-expandable valves.
Numerous studies have been published on
the safety and efﬁcacy of both device types
separately, and both technologies have
been associated with favorable short- andlong-term outcomes (1–7). However, comparative
data are scarce and have been derived mainly from
observational registries (8–11).SEE PAGE 801In CHOICE (Randomized Comparison of Trans-
catheter Heart Valves in High Risk Patients With Se-
vere Aortic Stenosis: Medtronic CoreValve Versus
Edwards SAPIEN XT), the ﬁrst head-to-head trial of
balloon- and self-expandable THVs, the use of a
balloon-expandable valve resulted in a greater rate of
device success than the use of a self-expandable
valve, while clinical outcomes at 30 days were com-
parable (12). In this report, we describe the 1-year
clinical outcomes and echocardiographic ﬁndings af-
ter TAVR with balloon- and self-expandable valves in
the CHOICE trial.
METHODS
STUDY DESIGN AND POPULATION. The study design
and patient selection of the CHOICE trial have been
previously described (12). Brieﬂy, this investigator-
initiated, multicenter, randomized controlled trial
included 241 patients with symptomatic severe
aortic stenosis at high risk for surgical aortic valve
replacement undergoing TAVR through the trans-
femoral route at 5 German centers. Patients had to
be anatomically suitable for treatment with both
balloon- and self-expandable valves, which was
deﬁned as a native aortic valve annulus measuring
20 to 27 mm in diameter on pre-procedural imaging.
Patients with pre-existing aortic bioprostheses and/orVascular and Boston Scientiﬁc; and has received lecture fees fro
fesciences. Dr. Kuck has received grants and personal fees from
thors have reported that they have no relationships relevant to
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received May 11, 2015; revised manuscript received June 2, 2015contraindications to transfemoral access were ex-
cluded. The study was in compliance with the
Declaration of Helsinki, the locally appointed ethics
committees approved the research protocol, and
written informed consent was obtained from all sub-
jects. An independent data-coordinating center, with
oversight from a steering committee, conducted the
data management and analysis. The members of the
steering committee had full access to the data and
vouch for the accuracy and completeness of the data
and the analyses.
STUDY DEVICES AND PROCEDURE. The devices used
in this study and the TAVR procedure have been pre-
viously described (12–14). The balloon-expandable
valve used in this trial (Edwards SAPIEN XT;
Edwards Lifesciences, Irvine, California) is a cylindri-
cal cobalt-chromium stent into which 3 leaﬂets made
of bovine pericardium are mounted, whereas the self-
expandable valve (Medtronic CoreValve; Medtronic
Inc., Minneapolis, Minnesota) consists of porcine
pericardial tissue sewn to form a trileaﬂet valve
mounted within a self-expanding hourglass-shaped
nitinol frame. Device size selection was based largely
on 3-dimensional multidetector computed tomogra-
phy–based annular measurements. Highly experi-
enced operators at centers with established
multidisciplinary TAVR programs performed all pro-
cedures, and these were mainly accomplished under
analgo-sedation (without endotracheal intubation)
using ﬂuoroscopic guidance. Antithrombotic treat-
ment recommendation consisted of aspirin 100 mg/
day indeﬁnitely and clopidogrel 75 mg for at least 3
months. Patients taking oral anticoagulant agents
mainly continued oral anticoagulation and were pre-
scribed clopidogrel for 3 months but no aspirin.
STUDY ENDPOINTS. The pre-speciﬁed primary end-
point of the CHOICE trial was “device success,” as
deﬁned by the ﬁrst Valve Academic Research Con-
sortium (VARC) consensus document (15) and has
been previously reported (12). All patients were
followed-up for at least 1 year and had clinical visits
and echocardiographic evaluations at 6 months and
1 year. Pre-speciﬁed secondary endpoints included
cardiovascular mortality, stroke, repeat hospitaliza-
tion for heart failure, New York Heart Association
(NYHA) functional class improvement (improvementm Abbott Vascular, Biotronik, Boston Scientiﬁc, and
St. Jude Medical, Biosense Webster, and Medtronic.
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793by at least 1 functional class), a combined efﬁcacy
endpoint (a composite of all-cause mortality bet-
ween 30 days and 1 year, failure of current therapy
for aortic stenosis requiring hospitalization for
symptoms of valve-related or cardiac decompensa-
tion, and prosthetic valve dysfunction, deﬁned as an
aortic valve area <1.2 cm2 and mean aortic valve
gradient >20 mm Hg or peak velocity >3 m/s or
moderate or severe prosthetic valve regurgitation),
and major adverse cardiovascular and cerebrovascu-
lar events (a composite of myocardial infarction, car-
diac or vascular surgery, and stroke). A clinical events
committee blinded to treatment assignment was
responsible for adjudicating all endpoints. Deﬁnitions
of the endpoints were identical to those in the original
trial (in accordance with the ﬁrst VARC consensus
document) and have been reported elsewhere (12,15).
Echocardiographic assessment was performed in
accordance with the VARC recommendations (15).
Aortic regurgitation (AR) was semiquantitatively
assessed by estimating the proportion of the circum-
ference of the valved stent occupied by the jet: <10%
was graded as mild, 10% to 20% as moderate, and
>20% as severe paravalvular AR (15,16). Evaluation
was performed on site by an experienced interven-
tional echocardiographer blinded to the echocardio-
graphic ﬁndings at discharge and/or 30 days.
STATISTICAL ANALYSIS. The sample size of the trial
was based on the original primary endpoint of deviceFIGURE 1 Study Flowchart
241 Transfemoral TAVR patien
Balloon-expandable valve
(Edwards Sapien XT, n = 121)
Alive = 116
Dead = 5
LTFU = 0
Withdrawal = 0
Alive = 100
Dead = 21
LTFU = 0
Withdrawal = 0
100% Clinical follow-up
30 d
1 ye
LTFU ¼ lost to follow-up; TAVR ¼ transcatheter aortic valve replacemesuccess, as previously described (12). With the sample
size of 241 patients and an annual mortality rate of
15%, the trial had approximately 50% power to detect
a 10% difference in 1-year mortality between both
treatment arms, with a 5% signiﬁcance level. All
clinical and echocardiographic endpoints were
analyzed on an intention-to-treat basis. Categorical
variables were compared using the Fisher exact test,
and the relative risk (RR) and 95% conﬁdence interval
(CI) were calculated using a standard method (17).
Continuous variables were compared using 2-sided
unpaired Student t test or Mann-Whitney U tests, as
appropriate. Survival curves for time-to-event vari-
ables were constructed using Kaplan-Meier estimates
on the basis of all available data and were compared
using log-rank tests. Death was treated as a censoring
event in the Kaplan-Meier analysis for all strokes and
rehospitalization for heart failure. All tests were
2-sided, and p values <0.05 were considered to
indicate statistical signiﬁcance. Statistical analyses
were performed using Minitab version 15 (Minitab
Inc., State College, Pennsylvania) and SAS version 9.4
(SAS Institute Inc., Cary, North Carolina). An inde-
pendent statistician performed all analyses.
RESULTS
PATIENTS. Two hundred forty-one patients under-
going transfemoral TAVR were enrolled between
March 2012 and December 2013; 121 patients werets enrolled and randomized
97% Clinical follow-up
Alive = 102
Dead = 15
LTFU = 0
Withdrawal = 3
Alive = 111
Dead = 6
LTFU = 1
Withdrawal = 2
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TABLE 1 Baseline Cl
Age, yrs
Women
Logistic EuroSCORE
Society of Thoracic Sur
New York Heart Associ
I
II
III
IV
Coronary artery disease
Previous myocardial in
Previous CABG
Previous PCI
Cerebral vascular disea
Peripheral vascular dise
Pulmonary disease
Creatinine level, mg/dl
Atrial ﬁbrillation
Permanent pacemaker
Echocardiography
Aortic valve area, cm
Mean gradient, mm
LV ejection fraction,
Values are mean  SD or n
CABG ¼ coronary artery b
LV ¼ left ventricular; PCI ¼
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794randomized to the balloon-expandable valve and 120
patients to the self-expandable valve. All patients
received the assigned TAVR device, with no cross-
overs. Figure 1 shows the study-group assignments
and follow-up. All patients were followed-up for
1 year. The overall study population was elderly
(mean age 81.5  6.2 years), had severe cardiac
symptoms (80.9% were in NYHA functional class III or
IV), and had frequent comorbid conditions (63.1% had
histories of coronary artery disease, 39.4% had un-
dergone previous percutaneous coronary interven-
tion, 14.1% had undergone previous coronary artery
bypass surgery, 17.4% had peripheral vascular dis-
ease, and 21.2% had pulmonary disease). The balloon-
and self-expandable groups were generally well
balanced with regard to baseline clinical and echo-
cardiographic characteristics (Table 1), except for sex
(43.0% men in the balloon-expandable group and
28.3% in the self-expandable group, p ¼ 0.02). The
mean logistic European System for Cardiac Operative
Risk Evaluation score was 21.8  13.8%, and the mean
Society of Thoracic Surgeons score was 5.9  3.5%.
CLINICAL OUTCOMES. Outcomes at 30 days have
been previously described (12). Between 30 days andinical Characteristics and Echocardiographic Findings
Balloon-Expandable
Valve
(n ¼ 121)
Self-Expandable
Valve
(n ¼ 120) p Value
81.9  6.7 79.6  15.8 0.14
69/121 (57.0) 86/120 (71.7) 0.02
21.5  12.9 22.1  14.7 0.72
geons score 5.6  2.9 6.2  3.9 0.17
ation functional class 0.79
7/121 (5.8) 4/120 (3.3)
17/121 (14.1) 18/120 (15.0)
73/121 (60.3) 74/120 (61.7)
24/121 (19.8) 24/120 (20.0)
73/121 (60.3) 79/120 (65.8) 0.38
farction 14/121 (11.6) 16/120 (13.3) 0.68
19/121 (15.7) 15/120 (12.5) 0.48
44/121 (36.4) 51/120 (42.5) 0.33
se 26/121 (21.5) 22/120 (18.3) 0.54
ase 20/121 (16.5) 22/120 (18.3) 0.88
27/121 (22.3) 24/120 (20.0) 0.66
1.1  0.4 1.2  0.5 0.18
39/117 (33.3) 29/117 (24.8) 0.15
7/117 (5.9) 9/117 (7.7) 0.60
2 0.7  0.2 0.7  0.2 0.71
Hg 43.3  15.4 43.0  13.9 0.90
% 52.5  13.8 54.9  11.9 0.15
/N (%).
ypass grafting; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
percutaneous coronary intervention.1 year, there were 16 additional deaths in the balloon-
expandable group and 9 in the self-expandable group.
At 1 year, there was no signiﬁcant evidence of a dif-
ference in mortality of any cause between the
balloon-expandable group (17.4%) and the self-
expandable group (12.8%; RR: 1.35; 95% CI: 0.73 to
2.50; p ¼ 0.37) (Table 2, Figure 2). Cardiovascular
mortality at 1 year was not statistically signiﬁcantly
different between the balloon- and self-expandable
groups (12.4% and 9.4%, respectively; RR: 1.32; 95%
CI: 0.63 to 2.75; p ¼ 0.54). Eight patients (4 from each
group) had sudden or unexplained death during the
follow-up period.
Between 30 days and 1 year, 5 strokes occurred
(4 in the balloon-expandable group and 1 in the self-
expandable group). The frequency of all strokes at
1 year was numerically but not statistically signiﬁ-
cantly higher with the balloon-expandable valve
compared with the self-expandable valve (9.1% vs.
3.4%; RR: 2.66; 95% CI: 0.87 to 8.12; p ¼ 0.11) (Table 2,
Figure 3). The composite of the rate of death of any
cause or stroke did not statistically signiﬁcantly differ
between the 2 treatment groups (21.5% vs. 15.4%; RR:
1.40; 95% CI: 0.81 to 2.41; p ¼ 0.25).
Other clinical events are summarized in Table 2.
Vascular and bleeding complications were observed
mainly during the periprocedural period, but after 30
days, these events were uncommon and did not sta-
tistically signiﬁcantly differ between the 2 treatment
groups. Endocarditis, as deﬁned by the modiﬁed
Duke criteria, was rare and was not statistically
signiﬁcantly different between both groups (2 cases
of deﬁnite endocarditis in the balloon-expandable
group and 1 case of possible endocarditis in the self-
expandable group). Between 30 days and 1 year,
7 patients required new pacemakers, all from the
balloon-expandable group. Nevertheless, the cumu-
lative rate of new pacemaker implantation at 1 year
remained higher in the self-expandable group (23.4%
vs. 38.0%; p ¼ 0.02). Overall, 49% of pacemaker im-
plantations were performed for indications other
than advanced atrioventricular block, with no statis-
tically signiﬁcant difference between the balloon- and
self-expandable groups (46.2% vs. 51.4%; p ¼ 0.80).
At 1 year, there was no statistically signiﬁcant dif-
ference in the rate of repeat hospitalization for heart
failure between the groups (7.4% in the balloon-
expandable group vs. 12.8% in the self-expandable
group; RR: 0.58; 95% CI: 0.26 to 1.27; p ¼ 0.19)
(Table 2, Figure 3). Of the 24 patients requiring rehos-
pitalization for heart failure during the follow-up
period, 6 had more than mild residual AR after TAVR,
all in the self-expandable group (40% of heart failure
hospitalizations in this group). Among survivors at 1
TABLE 2 Clinical Outcomes at 1 Year
Balloon-Expandable
Valve
(n ¼ 121)
Self-Expandable
Valve
(n ¼ 117) RR (95% CI) p Value
Death
Of any cause 21/121 (17.4) 15/117 (12.8) 1.35 (0.73–2.50) 0.37
Of cardiovascular causes 15/121 (12.4) 11/117 (9.4) 1.32 (0.63–2.75) 0.54
Stroke 11/121 (9.1) 4/117 (3.4) 2.66 (0.87–8.12) 0.11
Major stroke 7/121 (5.8) 4/117 (3.4) 1.69 (0.51–5.63) 0.54
Minor stroke 4/121 (3.3) 0/117 (0.0) — 0.12
Ischemic stroke 8/121 (6.6) 4/117 (3.4) 1.93 (0.60–6.25) 0.38
Hemorrhagic stroke 3/121 (2.5) 0/117 (0.0) — 0.25
Repeat hospitalization for heart failure 9/121 (7.4) 15/117 (12.8) 0.58 (0.26–1.27) 0.19
Myocardial infarction 1/121 (0.8) 1/117 (0.9) 0.97 (0.06–15.28) 1.00
Bleeding
Life threatening 17/121 (14.0) 15/117 (12.8) 1.10 (0.57–2.09) 0.85
Major 26/121 (21.5) 17/117 (14.5) 1.48 (0.85–2.58) 0.18
Minor 13/121 (10.7) 9/117 (7.7) 1.40 (0.62–3.14) 0.50
Vascular complications
Major 14/121 (11.6) 14/117 (12.0) 0.97 (0.48–1.94) 1.00
Minor 5/121 (4.1) 2/117 (1.7) 2.42 (0.48–12.22) 0.45
Endocarditis 2/116 (1.7) 1/111 (0.9) 1.91 (0.18–20.81) 1.00
Valve thrombosis 4/116 (3.4) 0/111 (0.0) — 0.12
Repeat procedure for valve-related dysfunction 2/121 (1.6) 3/117 (2.6) 0.64 (0.11–3.79) 0.68
New pacemaker 26/111 (23.4) 38/100 (38.0) 0.62 (0.41–0.94) 0.02
New-onset atrial ﬁbrillation 8/82 (9.8) 8/85 (9.4) 1.04 (0.41–2.63) 1.00
Combined efﬁcacy endpoint 24/116 (20.7) 31/111 (27.9) 0.74 (0.47–1.18) 0.22
MACCE 13/121 (10.7) 8/117 (6.8) 1.57 (0.68–3.65) 0.36
NYHA functional class improvement 82/95 (86.3) 85/95 (89.5) 0.96 (0.87–1.07) 0.66
Quality-of-life score 65  22 67  20 — 0.49
Values are n/N (%) or mean  SD, unless otherwise noted. The p values for event rates were calculated using Fisher exact tests.
CI ¼ conﬁdence interval; MACCE ¼ major adverse cardiovascular and cerebrovascular event(s); NYHA ¼ New York Heart Association; RR ¼ relative risk.
FIGURE 2 Time-to-Event Curves for All-Cause and Cardiovascular Mortality
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(A) Cumulative incidence curves for all-cause mortality by device type. (B) Cumulative incidence curves for cardiovascular mortality by device
type. Events were calculated using Kaplan-Meier methods, and the p values were calculated using log-rank tests.
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FIGURE 3 Time-to-Event Curves for All Strokes and Rehospitalization for Heart Failure
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(A) Cumulative incidence curves for stroke by device type. (B) Cumulative incidence curves for rehospitalization for heart failure by device type.
Events were calculated using Kaplan-Meier methods, and the p values were calculated using log-rank tests.
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796year, the majority of patients in both groups were in
NYHA functional class I or II (88.9% in the balloon-
expandable group and 93.9% in the self-expandable
group), and NYHA functional class improvement be-
tween baseline and 1 year was not statistically signiﬁ-
cantly different between the groups (86.3% vs. 89.5%;
p¼ 0.66). Quality-of-life score (on a scale ranging from
0 to 100) at 1 year was similar in both groups (mean 65
22 vs. 67  20; p ¼ 0.49).
Results of a landmark analysis for selected clinical
endpoints occurring between 30 days and 1 year are
shown in Table 3. All results were essentially un-
changed when sex was taken into account.
ECHOCARDIOGRAPHIC FINDINGS. Echocardiographic
follow-up at 1 year was performed in 89.6% of survi-
vors (89.0% of the balloon-expandable group and
90.2% of the self-expandable group) (Table 4). Similar
to the post-procedural and 30-day ﬁndings (12), more
than mild paravalvular and total AR were less com-
mon in the balloon-expandable group (1.1% vs. 12.1%,TABLE 3 Landmark Analysis of Key Clinical Outcomes Between 30 Da
Balloon-Expandable Valve
Death of any cause 16/116 (13.8)
Stroke 4/111 (3.6)
Ischemic stroke 3/111 (2.7)
Hemorrhagic stroke 1/111 (0.9)
Repeat hospitalization for heart failure 9/116 (7.8)
New pacemaker 7/89 (7.9)
Values are n/N (%). For mortality, patients who died during the ﬁrst 30 days were exclud
were excluded. The p values were obtained using Fisher exact tests.
Abbreviations as in Table 2.p ¼ 0.005, for paravalvular AR; 1.1% vs. 13.1%,
p ¼ 0.02, for total AR). Among 177 patients with
paired echocardiographic evaluations at hospital
discharge and 1 year, paravalvular AR remained un-
changed in 59.4% of patients, was improved in 20.3%,
and was worse in 20.3%, with no differences in the
evolution of AR over time between balloon- and self-
expandable valves (p ¼ 0.98) (Table 5, Online
Tables 1 and 2).
In contrast, the median transvalvular gradient
remained slightly but statistically signiﬁcantly higher
in the balloon-expandable group at 1 year (median
9 mm Hg [IQR: 7 to 12 mm Hg] vs. 8 mm Hg [IQR: 5 to
11 mm Hg]; p ¼ 0.004). Four patients of the balloon-
expandable group had elevations of mean trans-
valvular gradient and reductions of aortic valve area
recorded during the follow-up period, which were not
recorded post-procedurally (observed between 175
and 203 days after TAVR; the mean gradient was
higher than 30 mm Hg in all 4 patients). A mobileys and 1 Year
Self-Expandable Valve RR (95% CI) p Value
9/111 (8.1) 1.70 (0.78–3.69) 0.21
1/109 (0.9) 3.93 (0.45–34.59) 0.37
1/109 (0.9) 2.95 (0.31–27.89) 0.62
0/109 (0.0) — 1.00
13/110 (11.8) 0.66 (0.29–1.47) 0.37
0/58 (0.0) — 0.04
ed. For all other endpoints, patients who either died or had events in the ﬁrst 30 days
TABLE 4 Echocardiographic Follow-Up at 1 Year
Balloon-Expandable
Valve
Self-Expandable
Valve p Value
Number of patients 69 66
Effective oriﬁce area, cm2 1.7  0.4 1.8  0.6 0.34
Number of patients 68 66
Indexed effective oriﬁce area, cm2/m2 0.9  0.2 1.0  0.3 0.16
Number of patients 79 81
Mean gradient, mm Hg 9 (7–12) 8 (5–11) 0.004
Number of patients 88 91
Transvalvular aortic regurgitation 0.44
None/trace 86 (97.7) 86 (94.5)
Mild 2 (2.3) 5 (5.5)
Moderate 0 (0) 0 (0)
Severe 0 (0) 0 (0)
Number of patients 89 91
Paravalvular aortic regurgitation 0.01
None/trace 52 (58.4) 44 (45.6)
Mild 36 (40.4) 36 (39.6)
Moderate 1 (1.1) 11 (12.1)
Severe 0 (0) 0 (0)
Number of patients 89 92
Total aortic regurgitation 0.03
None/trace 51 (57.3) 42 (45.6)
Mild 37 (41.6) 38 (41.3)
Moderate 1 (1.1) 11 (12.0)
Severe 0 (0) 1 (1.1)
Left ventricular ejection fraction, % 58.9  10.9 57.3  11.8 0.37
Left ventricular end-systolic dimension, mm 32.6  8.8 34.6  8.1 0.10
Left ventricular end-diastolic dimension, mm 46.1  8.1 48.2  7.4 0.16
Systolic pulmonary artery pressure, mm Hg 28.4  10.5 32.3  13.0 0.06
Moderate/severe mitral regurgitation 13/88 (14.8) 28/90 (31.1) 0.01
Moderate/severe tricuspid regurgitation 12/85 (14.1) 20/88 (22.7) 0.14
Values are n, mean  SD, median (interquartile range), or n/N (%).
TABLE 5 Changes in PVL for Balloon- and Self-Expandable Valves:
Echocardiography at Discharge Compared With 1 Year (Patients With Data
at Both Time Points)
Change in
PVL Grade Between
Discharge and 1 Year
Balloon-Expandable
Valve
Self-Expandable
Valve p Value*
2 0/88 (0) 1/89 (1.1) 0.98
1 15/88 (17.0) 20/89 (22.5)
0 58/88 (65.9) 47/89 (52.8)
1 15/88 (17.0) 21/89 (23.6)
Values are n/N (%). *The p value for comparison between balloon- and self-expandable valves
obtained with the Mann-Whitney U test.
PVL ¼ paravalvular leak.
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797mass suspicious for thrombus was detected in 1 pa-
tient, and leaﬂet thickening and restricted motion
were observed in the remaining 3 patients. All 4 pa-
tients had completed at least 3 months of dual-
antiplatelet therapy (3 were on aspirin monotherapy
and 1 on dual-antiplatelet therapy at the time of
diagnosis). In all 4 patients, the transvalvular
gradient normalized with anticoagulant therapy,
suggesting a thrombotic etiology.
Consequently, prosthetic valve dysfunction as
deﬁned by the VARC was recorded in 2.6% of patients
in the balloon-expandable group and 11.7% of pa-
tients in the self-expandable group at 1 year
(p ¼ 0.009). The VARC-deﬁned combined efﬁcacy
endpoint at 1 year was not statistically signiﬁcantly
different between the groups (20.7% vs. 27.9%,
respectively; p ¼ 0.22).
DISCUSSION
The main ﬁndings of this 1-year analysis of the ran-
domized CHOICE trial are as follows: 1) paravalvular
regurgitation remained stable, without signiﬁcant
worsening or improvement during follow-up, with
both balloon- and self-expandable devices, and more
than mild forms remained lower with the balloon-
expandable valve; 2) probable valve thrombosis was
infrequent but was observed only in patients
receiving the balloon-expandable valve; and 3) mor-
tality was not statistically signiﬁcantly different at
1 year, but clinical events with a strong impact on
mortality tended to be different between both devices
(numerically lower repeat hospitalizations for heart
failure but higher stroke rates with the balloon-
expandable valve).
PARAVALVULAR LEAKS. The primary endpoint of
the CHOICE trial (device success) was driven largely
by differences in post-procedural AR rates favoring
the balloon-expandable valve (12). These differences
were observed using various methods of AR assess-
ment, including angiography (core laboratory
graded), echocardiography (site graded), and quanti-
tative cardiac magnetic resonance imaging shortly
after the procedure. Findings from the randomized
PARTNER (Placement of Aortic Transcatheter Valves)
trial have shown that paravalvular AR after the im-
plantation of a balloon-expandable valve remained
stable during follow-up (18). However, the majority of
patients with moderate or severe paravalvular AR
shortly after the implantation of a self-expandable
device in the randomized U.S. CoreValve trial had
only mild or no regurgitation at 1 year (3,4). This po-
tential improvement over time was attributed to the
use of computed tomographic assessment of aorticannular diameter for valve-size selection, higher
placement of the valve within the aortic annulus, and
sustained expansion of the nitinol frame of the self-
expanding device (3). Despite the use of computed
tomographic assessment in the vast majority of the
CHOICE population and the high placement of the
CENTRAL ILLUSTRATION 1-Year Outcomes After Transcatheter Aortic Valve Replacement With
Balloon-Expandable Versus Self-Expandable Valves
Abdel-Wahab, M. et al. J Am Coll Cardiol. 2015; 66(7):791–800.
The design of CHOICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic
CoreValve Versus Edwards SAPIEN XT) is illustrated, showing the results of its previously reported primary endpoint and the main secondary
endpoint at 1 year. TAVR ¼ transcatheter aortic valve replacement.
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799valve within the aortic annulus (5 mm below the
annular plane), we did not observe a reduction of
overall AR rates with the self-expanding valve over
time. In the self-expanding group of the CHOICE trial,
5 of 7 patients (71%) with moderate AR at discharge
had mild or no AR at 1 year, but 9 of 45 patients (20%)
with mild AR at discharge progressed to moderate AR,
resulting in a neutral effect on the overall incidence
of different AR grades observed during follow-up
echocardiography.
VALVE THROMBOSIS. An unexpected ﬁnding during
the 1-year follow-up period was the occurrence of
early prosthetic valve dysfunction possibly attri-
buted to valve thrombosis in 4 patients treated
with balloon-expandable valves (incidence of 3.4%).
Thrombosis of transcatheter valves was ﬁrst des-
cribed by Latib et al. (19) in a series of 3 patients
treated with the balloon-expandable Edwards SAPIEN
XT valve. In a recently published systematic review of
published cases, Córdoba-Soriano et al. (20) reviewed
a total of 11 publications describing 16 patients
thought to have developed valve thrombosis after
TAVR. All but 1 patient (94%) received balloon-
expandable valves, and all patients received dual-
antiplatelet therapy immediately after the procedure
and continued to receive either single- or dual-
antiplatelet therapy at the time of valve thrombosis
diagnosis. Valve thrombosis was diagnosed at a me-
dian of 6 months post-procedurally (similar to our
ﬁndings), and signiﬁcant increases in transvalvular
gradient and leaﬂet thickening were the most com-
mon echocardiographic features. In the majority of
patients, valve function was effectively restored with
anticoagulant therapy. Although it remains difﬁcult
to determine the exact mechanisms for these obser-
vations, it is likely that thrombosis after TAVR relates
to an interplay of various anatomic, procedural, and
valve-related factors (20). Differences in how the
prosthesis is deployed (balloon inﬂation vs. self-
expansion) and its adaptation on the ovular native
aortic annulus might provide different interactions
with the surrounding anatomic structures, potentially
promoting thrombosis (20,21). Importantly, no dif-
ferences in adjunctive antiplatelet or anticoagulant
therapy were observed in the CHOICE trial between
the treatment arms (Online Table 3).
CLINICAL OUTCOMES. Symptomatic improvement in
the CHOICE trial was maintained at 1 year, with
no statistically signiﬁcant differences between the
devices. Clinical endpoints, particularly all-cause
and cardiovascular mortality, were not statistically
signiﬁcantly different between the devices and were
comparable with contemporary outcome data withboth device types in Europe and the United States
(3–5,9,10,22). This is in line with previously published
registry data comparing balloon- and self-expandable
TAVR devices, which failed to show any difference in
survival at short- and intermediate-term follow-up
between the valves (7,9–11). Despite the differences in
relevant outcome measures such as paravalvular AR
and device success favoring the balloon-expandable
valve, and the association of device success with
improved survival in this trial (data not shown),
mortality rates were not statistically signiﬁcantly
different at 1 year (Central Illustration). This could be
partially explained by the moderate sample size of
this study, which was not powered to detect differ-
ences in clinical outcomes, and the ongoing “back-
ground” events of death that occur in patients in their
80s. However, a relevant clinical event associated
with mortality, such as stroke, tended to be less
common with the self-expandable device, which may
have counterbalanced the advantage of a higher de-
vice success rate in the balloon-expandable group. A
potential relationship between stroke and valve
thrombosis in the balloon-expandable group remains
speculative, as none of the patients with probable
valve thrombosis in this trial had thromboembolic
complications. In a recently published meta-analysis,
stroke rates were comparable between balloon- and
self-expandable valves at 30 days (3.0% vs. 2.4%,
respectively) (23). The rates of cerebrovascular events
at 1 year in the high-risk cohorts of the randomized
PARTNER and U.S. CoreValve trials were 8.3% and
8.8%, respectively (2,3).
STUDY LIMITATIONS. The 1-year ﬁndings of this trial
should be interpreted in the context of its moderate
sample size and the lack of power to detect differ-
ences in clinical outcomes. As previously described
(12), the lack of an echocardiographic core laboratory
remains a limitation of this trial. However, the echo-
cardiographic evaluation of the severity of para-
valvular leaks after TAVR remains complex and
challenging, and differences in grading have even
been observed within and between different echo-
cardiographic core laboratories (24).
CONCLUSIONS
Despite the higher device success rate and lower
paravalvular regurgitation rate (which remained sta-
ble during follow-up) with the balloon-expandable
valve, no statistically signiﬁcant differences in
1-year mortality rates were observed among the
CHOICE patients treated with either balloon- or
self-expandable valves, with limited statistical power.
The numerically higher rate of thromboembolic
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients undergoing TAVR because they would have
faced a high risk for complications with surgical aortic
valve replacement, there was no statistically signiﬁ-
cant difference in 1-year survival between balloon-
expandable and self-expandable devices.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to compare the safety and efﬁcacy of
available devices during long-term follow-up of
patients with aortic valve disease undergoing TAVR.
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scores the necessity of adequately powered large
comparative device trials in the TAVR ﬁeld.
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